法科学家发现:透析会增加氧化应激

根据一项最新研究发现:许多透析患者一直处于由透析治疗引起的慢性炎症状态,透析治疗增加了氧化应激,这种状态与远期并发症相关,例如心血管疾病、营养不良、预后不良以及存活率较低.

氧化应激是毒性产物与机体防御机制之间失去平衡的结果.在透析过程中发病率很高,氧化应激被认为与终末期肾脏疾病患者许多不良并发症相关.这种不平衡是由于反应性氧基团或者毒性产物生成过多,以及抗氧化剂缺乏不足以对抗这些毒素.血液透析过程能够导致这些必须抗毒素的丧失.

"通过提高血液透析系统的生物适应性以防止反应性氧基团生成十分重要."Jean-Paul Cristol医生指出.他是这项研究的通讯作者,法国Lapeyronie大学医院生化科主任.这项研究成果发表在2005年3月30日出版的《国际血液透析》杂志上.

通过特异或者非特异药物来增加抗毒素并调控反应性氧基团,是该篇论文中指出的可能解决方案.作者指出:纠正氧基团的不平衡是防止长期血透患者并发症的基本前提,而且是很有前景的研究途径.【本文由美迪医疗网成扬编译】
 
Dialysis Enhances Oxidative Stress
 
Many dialysis patients are in a state of chronic inflammation induced by the dialysis process, which further enhances oxidative stress, a state associated with long-term complications such as cardiovascular disease, malnutrition, poor outcome, and low survival, according to a new study.

Oxidative stress (OS) is the result of an imbalance between toxic compounds and defense mechanisms. Prevalent in the dialysis process, it has been linked to numerous adverse complications in end-stage renal disease patients. The imbalance is caused by the overproduction of reactive oxygen species (ROS), or toxic compounds, and the lack of antioxidants to fight these toxins. The hemodialysis process can cause loss of these necessary antitoxins.

“It is important to prevent reactive oxygen species production by improving the biocompatibility of the hemodialysis system,” observed Dr. Jean-Paul Cristol, M.D., corresponding author of the study and head of the biochemistry department at Lapeyronie University Hospital (Montpellier, France). The study was published in the March 30, 2005, issue of Hemodialysis International.

Antioxidant supplement and ROS modulation by specific or nonspecific drugs, such as statins, are possible solutions outlined in the article. “Correction of OS imbalance appears to be a basic requisite to prevent complications in long-term dialysis patients” and is “a promising avenue of research,” said the authors.